Jump Financial LLC Raises Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Jump Financial LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 196.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,488 shares of the company’s stock after purchasing an additional 3,636 shares during the quarter. Jump Financial LLC’s holdings in IDEXX Laboratories were worth $2,269,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Geode Capital Management LLC boosted its holdings in IDEXX Laboratories by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock worth $948,279,000 after buying an additional 37,734 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after acquiring an additional 34,305 shares in the last quarter. Invesco Ltd. grew its stake in IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock valued at $479,999,000 after acquiring an additional 74,324 shares during the period. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $412,258,000. Finally, American Century Companies Inc. increased its stake in shares of IDEXX Laboratories by 30.9% during the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company’s stock worth $334,810,000 after purchasing an additional 191,385 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $411.72 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The stock has a 50 day moving average price of $422.37 and a 200 day moving average price of $431.22. The company has a market capitalization of $33.37 billion, a price-to-earnings ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

Wall Street Analysts Forecast Growth

Several research firms have commented on IDXX. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 12th. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $523.75.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.